Novo Nordisk to slash prices of weightloss drugs in US / Photo: © GETTY IMAGES NORTH AMERICA/AFP/File
-
Salah says 'had to do it' after coolest of penalties in World Cup win
-
England seek end to Australia agony in Women's World Cup final
-
Australia's Popovic on defensive as gamble fails in World Cup exit
-
President-elect Fujimori hails 'new chapter' for Peru
-
Maiden ton for Udara as Sri Lanka pile on the runs in 2nd Test
-
Global celebrities pay court at Swift, Kelce "royal wedding"
-
Norway pin hopes on Haaland against Brazil in World Cup last 16
-
Dangerous heat wave roasts America's big birthday party
-
Egypt down Australia to reach World Cup last 16, Cape Verde face Messi
-
Egypt edge Australia on penalties to reach World Cup last 16
-
Families demand help with recovering Venezuela's quake victims
-
France braced for extreme heat threat in World Cup clash with Paraguay
-
England's Rashford unfazed by high-altitude Mexico World Cup test
-
Iranians begin to gather for Khamenei funeral ceremonies
-
In Brazil, Bolsonaro family airs feud ahead of elections
-
England v Mexico World Cup kickoff could be moved earlier: source
-
Postecoglou links up with Ronaldo at Al Nassr
-
Frustrated families demand recovery of Venezuela's earthquake dead
-
Sabalenka sets up Wimbledon last-16 clash with Osaka
-
Williams sisters return, Swiatek faces Eala test at Wimbledon
-
Dangerous heatwave hits peak temps along US east coast
-
'Ecstatic' Hamilton rolls back the years with Silverstone pole
-
LeBron's agent makes case for 10 new clubs for 41-year-old star
-
England enter World Cup lion's den as Mexico host them at Azteca fortress
-
Trump heads for Mount Rushmore as US turns 250
-
Hamilton beats Antonelli to British GP sprint pole with supreme lap
-
French Top 14 champions Toulouse fined for salary cap breaches
-
Title rivals Djokovic and Sinner advance at Wimbledon
-
Record-equalling Djokovic powers into Wimbledon last 16
-
Ferrari confirm Hamilton staying next year
-
Ruthless Sinner powers into Wimbledon last 16
-
Global frenzy over Swift, Kelce's glittering 'royal wedding'
-
England's Kane feels 'as good as ever' ahead of Mexico World Cup clash
-
Three acquitted of 2019 murder of N.Irish journalist Lyra McKee
-
French Top 14 champions Toulouse fined for salary breaches
-
Stokes bids farewell to fans after 'mad 15 years'
-
Thousands more head for South Africa's borders
-
One for the history books: what we know about the European heatwave
-
Australia upbeat about 'ultimate professional' Perry's fitness for World Cup final
-
Dutch FA to sue over racist slurs after World Cup exit
-
Ukraine backers to vow major support at NATO summit
-
Mercedes demos set stage for wave of German auto protests
-
Ayuso happy to fly under radar at Tour de France
-
Iran leaders pay last respects to Khamenei as mourners gather
-
Curran ready to fill England gap left by Stokes exit
-
UN issues 'red alert' over 'catastrophe' in Sudan's El-Obeid
-
Djokovic has history on the line at Wimbledon
-
Tour de France to start with team time-trial 'bang'
-
Dressed for success: Osaka reaches Wimbledon last 16 for first time
-
Hamilton sparkles in Silverstone sunshine
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
M.Ouellet--BTB